| Literature DB >> 31067253 |
Kathryn A Murray1,2,3, Caroline L Hoad1,2, Jill Garratt2, Mehri Kaviani1, Luca Marciani2, Jan K Smith2, Britta Siegmund4, Penny A Gowland1, David J Humes2, Robin C Spiller2.
Abstract
BACKGROUND: Complications of diverticular disease are increasingly common, possibly linked to increasing obesity. Visceral fat could contribute to the development of symptomatic diverticular disease through its pro-inflammatory effects.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31067253 PMCID: PMC6505945 DOI: 10.1371/journal.pone.0216528
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CONSORT flow diagram for the study.
The CONSORT checklist can be found in S1 Checklist in the Supporting Information.
Characteristics of symptomatic and asymptomatic patients with diverticulosis.
| Symptomatic | Asymptomatic | ||
|---|---|---|---|
| 64 (54–70) | 66 (57–69) | 0.7 | |
| % Female | 60.5 | 47.1 | |
| % Male | 39.5 | 52.9 | |
| 29.0 (4.7) | 28.3 (4.9) | 0.7 | |
| 1.2 (0.6–2.9) | 0 | 0.0001 | |
| 1.7 (1.3–2.1) | 1.6 (1.4–2.4) | 1.0 | |
| 9.0 (6.8–11.0) | 4.0 (2.0–7.5) | 0.0003 | |
| Anxiety | 6.0 ± 4.2 | 4.2 ± 3.3 | 0.14 |
| Depression | 3.5 (1.8–6.0) | 2.0 (1.0–3.5) | 0.09 |
| 2 | 2 | ||
| 6 | 1 | 0.42 |
a Normally distributed data are shown as mean (SD) while median (IQR) is used for non-normally distributed data
b P values are calculated using unpaired t tests for normally distributed data and Mann-Whitney tests when non-normal
Fig 2Fat only mDIXON image of the abdominal region of a patient with diverticular disease.
The portion of the colon with the diverticula is highlighted in the boxed image. The image was collected using a T1 weighted, water suppressed, sequence where adipose tissue appears bright and allows for its quantification. The colon and other organs appear darkly coloured, providing a contrast for visualisation of the diverticula.
Adipokines in symptomatic and asymptomatic patients.
Data are shown as median (IQR).
| Symptomatic | Asymptomatic | P | |
|---|---|---|---|
| 4.2 (3.0–6.8) | 3.9 (2.5–6.2) | 0.8 | |
| 14.6 (5.9–32.5) | 10.79 (4.2–18.9) | 0.2 | |
| 44.6 (26.7–116.3) | 46.3 (23.6–68.2) | 0.6 |
Fig 3Correlations between adipokines and measures of adipose tissue.
Some of the stronger correlations between leptin, adiponectin and MRI measures of fat volume. * = P <0.05, ** = P <0.005, *** = P <0.001.
Association between bowel symptoms and objective measures of adiposity, adipokines and calprotectin.
| Spearman ρ | |||
|---|---|---|---|
| BMI | 0.4 | 0.005 | |
| Adiponectin | -0.3 | 0.0095 | |
| VAT | 0.3 | 0.03 | |
| VAT | -0.3 | 0.03 | |
| VAT/SAT | -0.4 | 0.004 | |
| Adiponectin | 0.5 | 0.0002 | |
| BMI | -0.4 | 0.0008 | |
| Calprotectin | -0.4 | 0.009 | |
Comparison of manual and semi-automatic definitions of adipose tissue regions (N = 10) obtained across 30 slices.
| VOLUMES (ml) | RATIOS | ||||
|---|---|---|---|---|---|
| VAT | SAT | TAT | VAT/SAT | VAT/TAT | |
| 1020±310 | 2540±1180 | 3660±1350 | 0.46±0.19 | 0.29±0.08 | |
| 620–1490 | 1000–5230 | 2030–6690 | 0.20–0.85 | 0.16–0.42 | |
| 1020±320 | 2540±1170 | 3660±1350 | 0.46±0.19 | 0.29±0.08 | |
| 600–1500 | 1000–5230 | 2030–6690 | 0.20–0.86 | 0.16–0.42 | |
| -0.2 | -27.8 | 0.0 | 0.004 | -0.001 | |
| -25.2 to 24.8 | -62.4 to 6.8 | -0.2 to 0.2 | -0.008to 0.016 | -0.009 to 0.007 | |
| 0.983±0.009 | 0.994±0.002 | 1.000±0.000 | N/A | N/A | |